The Risks of Prescription Drugs (A Columbia / SSRC Book (Privatization of Risk))
معرفی کتاب «The Risks of Prescription Drugs (A Columbia / SSRC Book (Privatization of Risk))» نوشتهٔ edited by Donald W. Light، منتشرشده توسط نشر Columbia University Press در سال 2010. این کتاب در فرمت pdf، زبان انگلیسی ارائه شده است.
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Donald W. Light is professor of social medicine and comparative health care at the University of Medicine and Dentistry of New Jersey and a senior visiting researcher at Princeton. Publisher's note Bearing The Risks Of Prescription Drugs / Donald Light -- The Food And Drug Administration : Inadequate Protection From Serious Risks / Donald Light -- The Commercialization Of Medical Decisions : Physicians And Patients At Risk / Howard Brody -- Pharmaceuticals And The Medicalization Of Social Life / Allan Horwitz -- Medicalization And Risk Scares : The Case Of Menopause And Hrt / Cheryl Stults And Peter Conrad -- Toward Safer Prescribing And Better Drugs / Donald Light. Edited By Donald W. Light. Includes Bibliographical References And Index. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the prvate sector and markets a greater role and reducing public oversight? This book considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals--Cover Content: Bearing the risks of prescription drugs / Donald Light -- The Food and Drug Administration : inadequate protection from serious risks / Donald Light -- The commercialization of medical decisions : physicians and patients at risk / Howard Brody -- Pharmaceuticals and the medicalization of social life / Allan Horwitz -- Medicalization and risk scares : the case of menopause and HRT / Cheryl Stults and Peter Conrad -- Toward safer prescribing and better drugs / Donald Light. Contents 6 Chapter 1. Bearing the Risks of Prescription Drugs 12 Chapter 2. The Food and Drug Administration: Inadequate Protection from Serious Risks 51 Chapter 3. The Commercialization of Medical Decisions: Physicians and Patients at Risk 81 Chapter 4. Pharmaceuticals and the Medicalization of Social Life 103 Chapter 5. Medicalization and Risk Scares:The Case of Menopause and HRT 127 Epilogue: Toward Safer Prescribing and Better Drugs 151 Contributors 177 Bearing the risks of prescription drugs / Donald Light The FDA : inadequate protection from drug disasters and serious risks / Donald Light The commercialization of medical decisions : physicians and patients at risk / Howard Brody Pharmaceuticals and the medicalization of social life / Allan Horwitz Medicalization and risk scares : the case of menopause and HRT / Cheryl Stults and Peter Conrad.
دانلود کتاب The Risks of Prescription Drugs (A Columbia / SSRC Book (Privatization of Risk))